• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Management of Anticoagulation in Cancer Patients with Atrial Fibrillation
Isr Med Assoc J. 2022 Mar;24(3):183-185.ABSTRACTAtrial fibrillation is becoming an increasingly important problem in cardio-oncology. Specific risk factors for atrial fibrillation occurrence include type of cancer disease and anticancer drugs. Anticoagulation is often abandoned. The CHA2DS2-VASc and CHA2DS2 scores may be important not only in predicting stroke but also in mortality. The role of new direct oral anticoagulants is growing, but they need to be used in a personalized approach depending on the risk of unbeneficial interactions with cancer treatment and the risk of bleeding.PMID:35347933
Source: The Israel Medical Association Journal - March 29, 2022 Category: General Medicine Authors: Sebastian Szmit Jaros ław Kępski Michal Wilk Source Type: research

Cancers, Vol. 15, Pages 2574: Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients
Conclusions: Anticoagulation with DOACs provides a higher safety profile with respect to VKAs in terms of stroke reduction and a relative bleeding reduction risk. Further studies are needed to better assess the optimal anticoagulation strategy in cancer patients with AF.
Source: Cancers - April 30, 2023 Category: Cancer & Oncology Authors: Alberto Cereda Stefano Lucreziotti Antonio Gabriele Franchina Alessandra Laricchia Valentina De Regibus Barbara Conconi Matteo Carl à Andrea Spangaro Matteo Rocchetti Luca Ponti Alessandro Minardi Elena Sala Giuseppe Massimo Sangiorgi Gabriele Tumminello Tags: Review Source Type: research

< em > ABCG2 < /em > Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
CONCLUSION: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.PMID:37641689 | PMC:PMC10460569 | DOI:10.2147/DDDT.S417096
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Hamin Kim Tae-Jin Song Jeong Yee Dong-Hyeok Kim Junbeom Park Hye Sun Gwak Source Type: research

Comparative Bleeding Risk in Patients with Atrial Fibrillation with Cancer versus Without Cancer from Nationwide Prospective Cohort
This study aimed to clarify the differences in the bleeding risk in patients with AF with cancers and those without cancers during the long-term OAC.The CODE-AF prospective registry enrolled 5,902 consecutive patients treated for AF at 10 tertiary referral centers in Korea. Of the enrolled patients, 464 (7.8%) were diagnosed with cancers and were followed for all stroke and bleeding events (net composite events).The age, CHA2DS2-VASC, and HAS-BLED scores were similar between AF patients with and without cancers. Male population greatly comprised patients with AF with cancers. They were equally prescribed with direct OAC co...
Source: International Heart Journal - September 13, 2023 Category: Cardiology Authors: Ki-Woon Kang David Shin Seung Young Shin Jun Kim Eu-Keun Choi Myung-Jin Cha Jung-Myung Lee Jin-Bae Kim Junbeom Park Jin-Kyu Park Tae-Hoon Kim Jae-Sun Uhm Jaemin Shim Young Soo Lee Hyung Wook Park Changsoo Kim Boyoung Joung Source Type: research

Pages: 1  2  3  4  5  6  7